PDS Biotechnology Corporation(PDSB)

Description: PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

---

Keywords: Medicine Biotechnology Cancer Clinical Medicine Oncology Immunotherapy Breast Cancer Cancer Immunotherapy Prostate Cancer Immunotherapies Melanoma Lipid Treatment Of Breast Cancer Head And Neck Cancer Cervical Cancer Oncolytics Biotech Treatment Of Melanoma Northwest Biotherapeutics Anal Cancer Muc1

---

Home Page: www.pdsbiotech.com

PDSB Technical Analysis

25B Vreeland Road
Florham Park, NJ 07932
United States
Phone: 800 208 3343

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)